Published in New England Journal of Medicine · View the paper (DOI)
A single-dose of the antiviral drug peginterferon lambda reduced the risk of hospitalization or Emergency Department visit due to COVID-19 by half in high-risk patients. The treatment was effective across different variants of concern, including Omicron, and showed minimal side effects.
Coverage from 2 institutions
- Single-dose treatment reduces risk of COVID-19 hospitalization by half for high-risk patients in a largely vaccinated population University Health Network · Feb 8, 2023 · first to report
- McMaster-led trial reduces COVID-19 hospitalization risk with single injection McMaster University · Feb 9, 2023